Obesity-Related Heart Failure

CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.

Semaglutide 2.4 mg was linked to early, sustained improvement in exercise function among patients with obesity-related HF and improved most among those with the largest proportionate weight loss, a speaker reported.

Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.

In a phase 2a trial of patients with obesity-related HF with preserved ejection fraction, a novel controlled metabolic accelerator was associated with weight loss at 3 months compared with placebo.

HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.